Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -9.71% is 61% above its 5-year average of -25.00%, near the high end of its 5-year range (-68.17%–2.54%).
56.74% below its 12-month average of -6.19%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2.20%.
EBITDA MARGIN
-9.71%
EBITDA MARGIN AVG TTM
-6.19%
EBITDA MARGIN AVG 3Y
-12.30%
EBITDA MARGIN AVG 5Y
-25.00%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-56.74%
CURRENT VS 3Y AVG
+21.08%
CURRENT VS 5Y AVG
+61.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$491.55M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$487.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481.33M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$478.54M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$471.57M
EBITDA Margin
-3.52%
TTM Avg
-5.19%
3Y Avg
-11.78%
5Y Avg
-23.46%
Market Cap
$517.73M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
Market Cap
$517.79M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $491.93M | -9.71% | -6.19% | -12.30% | -25.00% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 0.24% | -1.36% | -6.49% | -5.53% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | -41.77% | -67.13% | -207.81% | -270.93% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -31.76% | -31.76% | -31.76% | -31.76% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.52% | -5.19% | -11.78% | -23.46% |
| NRC Health (NRC)vs › | $468.31M | 21.99% | 25.40% | 28.98% | 31.97% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
Gross Margin
66.3%
EBITDA Margin
-9.7%
Operating Margin
-7.3%
Net Margin
-10.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2.20% |
| 2026-03-31 | -5.71% |
| 2025-12-31 | 2.54% |
| 2025-09-30 | -13.85% |
| 2025-06-30 | -11.76% |
| 2025-03-31 | -19.48% |
| 2024-12-31 | -1.19% |
| 2024-09-30 | -23.25% |
| 2024-06-30 | -9.15% |
| 2024-03-31 | -12.41% |
| 2023-12-31 | -11.91% |
| 2023-09-30 | -23.92% |
| 2023-06-30 | -27.67% |
| 2023-03-31 | -25.48% |
| 2022-12-31 | -22.02% |
| 2022-09-30 | -50.08% |
| 2022-06-30 | -55.15% |
| 2022-03-31 | -42.84% |
| 2021-12-31 | -49.36% |
| 2021-09-30 | -68.17% |
| 2021-06-30 | -51.91% |
| 2021-03-31 | 82.17% |
| 2020-12-31 | -515.87% |
| 2020-09-30 | -52.81% |
| 2020-06-30 | -149.62% |
| 2020-03-31 | -241.63% |
| 2019-12-31 | -75.70% |
| 2019-09-30 | -180.43% |
| 2019-06-30 | -1502.16% |
